Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy
Clicks: 171
ID: 110514
1996
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
171 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #108 of 149 articles by views in JAMA
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 149 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective. —To compare safety and efficacy of lamivudine-zidovudine combination therapy with zidovudine monotherapy in treating human immunodeficiency virus type 1 (HIV-1)—infected, antiretroviral therapy—naive patients. Design. —Double=blind, randomized, multicenter, comparative trial of 129 patients throughout 24 weeks followed by 24 weeks of open-label lamivudine in combination with zidovudine. Setting. —Outpatients from...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (49 words).
Try re-searching for a better abstract.
| Reference Key |
katlama1996jamasafety
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Christine Katlama;Didier Ingrand;Clive Loveday;Nathan Clumeck;Jose Mallolas;Schlomo Staszewski;Margaret Johnson;Andrew M. Hill;Gill Pearce;Hugh McDade; |
| Journal | JAMA |
| Year | 1996 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.